Primer: Biocytogen Pharmaceuticals (2315 HK) - Aug 2026
Biocytogen operates a dual-engine business model, combining a stable, revenue-generating preclinical Contract Research Organization (CRO)...
93 Views
𝛼SK or SearchENTITY
Biocytogen Pharmaceuticals (2315 HK)
Biocytogen Pharmaceuticals (2315 HK)
74
Analysis
Industrials • China
Biocytogen Pharmaceuticals is a global biotechnology company focused on the research and development of novel antibody-based drugs and preclinical research services. It offers gene-editing services, preclinical pharmacology and efficacy evaluation, and sells animal models under its BioMice™ sub-brand. The company also utilizes its proprietary RenMice® platforms for fully human antibody discovery. It was founded in 2008 and is headquartered in Beijing, China.
morex